Integrity,Innovation,Reliability,Responsibility

A Major Milestone! Phase III Clinical Trial Approved for High-Risk Biochemical Recurrence (BCR) Prostate Cancer, with Deutenzalutamide Soft Capsules as the Investigational Drug

Time:2026-07-16 Source:海创药业 Hits:175

Recently, Hinova Pharmaceuticals (688302.SH) received approval from the National Medical Products Administration (NMPA) of China for a Phase III clinical trial of Deutenzalutamide Soft Capsules for the treatment of high-risk biochemical recurrence (BCR) prostate cancer. This study is a randomized, double-blind, placebo-controlled Phase III trial comparing Deutenzalutamide combined with androgen deprivation therapy (ADT) versus placebo combined with ADT in patients with high-risk biochemical recurrence (BCR) prostate cancer.


About Deutenzalutamide

Deutenzalutamide Soft Capsules (formerly known as HC-1119 Soft Capsules) are a Class 1 new drug independently developed by the Company. It is a second-generation androgen receptor (AR) inhibitor and has received support from the National "Major New Drug Creation" Science and Technology Major Project. Deutenzalutamide Soft Capsules were approved for marketing by China's National Medical Products Administration on May 27, 2025, for the treatment of adult patients with metastatic castration-resistant prostate cancer (mCRPC) who have experienced disease progression after treatment with abiraterone acetate and chemotherapy and who have not previously received novel androgen receptor inhibitors. It has also been formally included in the "National Basic Medical Insurance, Maternity Insurance, and Work-Related Injury Insurance Drug Directory (2025)." Deutenzalutamide significantly prolongs progression-free survival (PFS) and reduces the risk of disease progression or death by 42% (HR=0.58, 95% CI: 0.439–0.770; p=0.0001). Compared with other novel endocrine therapies, Deutenzalutamide demonstrates an lent safety profile, with a significantly reduced incidence of central nervous system adverse events (such as seizures and falls), no rash-related adverse reactions, and a reduced risk of common complications in elderly patients.


The new indication under investigation involves combination with androgen deprivation therapy (ADT) for the treatment of high-risk biochemical recurrence (BCR) prostate cancer. This aims to delay disease progression and improve long-term survival outcomes for patients experiencing recurrence after radical treatment for early-stage prostate cancer, addressing unmet clinical needs and expanding the product's future market potential.


前列腺癌 Prostate Cancer

Prostate cancer is the most common malignant tumor in men in urology. According to GLOBOCAN statistics, there were 1.467 million new cases of prostate cancer globally in 2022. According to data from the National Cancer Center, there were 134,000 new cases and 47,000 deaths from prostate cancer in China in 2022. According to the literature "Burden of prostate cancer in China during 1990–2021 and the projections through 2050," the age-standardized prevalence rate (ASPR) of prostate cancer in China was 59.86 per 100,000 persons, leading to an estimated 550,000–600,000 prevalent prostate cancer cases in China in 2021.


Based on the literature "Incidence and prognostic implications of prostate-specific antigen persistence and relapse after radical prostatectomy: a population-based study" and the 2022 and 2025 CSCO Guidelines for the Diagnosis and Treatment of Prostate Cancer, the cumulative incidence of biochemical recurrence at 5, 10, and 15 years after radical prostatectomy was 31.7%, 34.3%, and 44.0%, respectively. Regarding the current approval landscape for drugs in China, no AR inhibitor has been approved for the indication of high-risk biochemical recurrence (BCR) prostate cancer.


Disclaimer:

1. This article is intended solely to share updates on academic frontiers and is for reference by healthcare professionals for academic purposes only. It is not promotional material. Hinova Pharmaceuticals does not make any recommendation, commitment, or guarantee regarding any drug or indication.

2. Any information involving unapproved products refers to assets still in development or clinical trials and involves uncertainties. Final outcomes are subject to approval by the National Medical Products Administration.

3. Risk Warning: Any forward-looking statements in this article regarding judgments of the external environment, corporate development strategies, future plans, etc., do not constitute substantive commitments by the Company to investors. Investors are advised to invest rationally and be aware of investment risks.